{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:38:01Z","timestamp":1789699081121,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00417-020-04977-1","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T13:03:09Z","timestamp":1603976589000},"page":"855-872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The polyp regression rate and treatment prognosis of different interventions for polypoidal choroidal vasculopathy: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"259","author":[{"given":"Xin-yu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-fei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-hui","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-5058","authenticated-orcid":false,"given":"You-xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"issue":"5","key":"4977_CR1","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","volume":"125","author":"CMG Cheung","year":"2018","unstructured":"Cheung CMG, Lai TYY, Ruamviboonsuk P, Chen SJ, Chen YX, Freund KB, Gomi F, Koh AH, Lee WK, Wong TY (2018) Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology 125(5):708\u2013724","journal-title":"Ophthalmology"},{"issue":"4","key":"4977_CR2","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/IAE.0b013e3182852446","volume":"33","author":"AH Koh","year":"2013","unstructured":"Koh AH, Expert PCV Panel, Chen LJ, Chen SJ, Chen YX, Giridhar A, Iida T, Kim H, Lai TYY, Lee KW, Li XX, Lim TH, Ruamviboonsuk P, Sharma T, Tang S, Yuzawa M (2013) Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina 33(4):686\u2013716","journal-title":"Retina"},{"issue":"1","key":"4977_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12886-019-1156-4","volume":"19","author":"X Gu","year":"2019","unstructured":"Gu X, Yu X, Dai H (2019) Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy. BMC Ophthalmol 19(1):153","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"4977_CR4","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3390\/jcm4050782","volume":"4","author":"CW Wong","year":"2015","unstructured":"Wong CW, Wong TY, Cheung CM (2015) Polypoidal choroidal vasculopathy in Asians. J Clin Med 4(5):782\u2013821","journal-title":"J Clin Med"},{"key":"4977_CR5","doi-asserted-by":"crossref","unstructured":"Teo KYC, Gillies M, Fraser-Bell S(2018) The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration. Int J Mol Sci 19(9):2611","DOI":"10.3390\/ijms19092611"},{"issue":"2","key":"4977_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000354546","volume":"231","author":"HM Kang","year":"2014","unstructured":"Kang HM, Koh HJ (2014) Two-year outcome after combination therapy for polypoidal choroidal vasculopathy: comparison with photodynamic monotherapy and anti-vascular endothelial growth factor monotherapy. Ophthalmologica 231(2):86\u201393","journal-title":"Ophthalmologica"},{"issue":"3","key":"4977_CR7","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ajo.2013.11.015","volume":"157","author":"HM Kang","year":"2014","unstructured":"Kang HM, Koh HJ, Lee CS (2014) Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome. Am J Ophthalmol 157(3):598\u2013606.e1","journal-title":"Am J Ophthalmol"},{"key":"4977_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","volume":"204","author":"TY Wong","year":"2019","unstructured":"Wong TY, Ogura Y, Lee WK, Iida T, Chen SJ, Mitchell P, Cheung CMG, Zhang ZQ, Leal S, Ishibashi T, Investigators P (2019) Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study. Am J Ophthalmol 204:80\u201389","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"4977_CR9","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell T, Cheung GCM, Zhang Z, Leal S, Ishibashi T, PLANET Investigators (2018) Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol 136(7):786\u2013793","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"4977_CR10","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, Tan CS, Feller C, Margaron P, Lim TH, Lee WK, EVEREST II study group (2017) Efficacy and safety of Ranibizumab with or without Verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol 135(11):1206\u20131213","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"4977_CR11","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1097\/IAE.0000000000000526","volume":"35","author":"F Gomi","year":"2015","unstructured":"Gomi F, Oshima Y, Mori R, Kano M, Saito M, Yamashita A, Iwata E, Maruko R, Fujisan Study Group (2015) Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: the Fujisan study. Retina 35(8):1569\u20131576","journal-title":"Retina"},{"issue":"8","key":"4977_CR12","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32(8):1453\u20131464","journal-title":"Retina"},{"issue":"10","key":"4977_CR13","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1097\/IAE.0b013e3182899296","volume":"33","author":"HJ Cho","year":"2013","unstructured":"Cho HJ, Baek JS, Lee DW, Cho SW, Kim CG, Kim JW (2013) Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Retina 33(10):2126\u20132132","journal-title":"Retina"},{"issue":"5","key":"4977_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/bjophthalmol-2012-302652","volume":"97","author":"T Hikichi","year":"2013","unstructured":"Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami T, Ohtsuka H, Kitamei H, Shioya S (2013) Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy. Br J Ophthalmol 97(5):617\u2013621","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"4977_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ajo.2012.06.027","volume":"155","author":"A Yamashita","year":"2013","unstructured":"Yamashita A, Shiraga F, Shiragami C, Shirakata Y, Fujiwara A (2013) Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 155(1):96\u2013102.e1","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"4977_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ajo.2012.02.019","volume":"154","author":"WK Lee","year":"2012","unstructured":"Lee WK, Kim KS, Kim W, Lee SB, Jeon S (2012) Responses to photodynamic therapy in patients with polypoidal choroidal vasculopathy consisting of polyps resembling grape clusters. Am J Ophthalmol 154(2):355\u2013365.e1","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"4977_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ajo.2011.12.019","volume":"154","author":"T Hikichi","year":"2012","unstructured":"Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, Ohtsuka H, Ariga H (2012) One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol 154(1):117\u2013124.e1","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"4977_CR18","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1097\/IAE.0b013e318236e835","volume":"32","author":"F Ricci","year":"2012","unstructured":"Ricci F, Calabrese A, Regine F, Missiroli F, Ciardella AP (2012) Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy. Retina 32(7):1280\u20131288","journal-title":"Retina"},{"issue":"3","key":"4977_CR19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/IAE.0000000000002384","volume":"40","author":"JH Cho","year":"2020","unstructured":"Cho JH, Park YJ, Cho SC, Ryoo NK, Cho KH, Park SJ, Park KH, Woo SJ (2020) Posttreatment polyp regression and risk of massive submacular hemorrhage in eyes with polypoidal choroidal vasculopathy. Retina 40(3):468\u2013476","journal-title":"Retina"},{"issue":"3","key":"4977_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1001\/jamaophthalmol.2019.5628","volume":"138","author":"B Doble","year":"2020","unstructured":"Doble B, Finkelstein EA, Tian Y, Saxena N, Patil S, Wong TY, Cheung CMG (2020) Cost-effectiveness of intravitreal ranibizumab with verteporfin photodynamic therapy compared with ranibizumab monotherapy for patients with polypoidal choroidal vasculopathy. JAMA Ophthalmol 138(3):251\u2013259","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"4977_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0002-9394(02)01516-7","volume":"134","author":"M Quaranta","year":"2002","unstructured":"Quaranta M, Mauget-Fa\u00ffsse M, Coscas G (2002) Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Am J Ophthalmol 134(2):277\u2013280","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"4977_CR22","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/eye.2014.222","volume":"28","author":"M Ho","year":"2014","unstructured":"Ho M, Lo EC, Young AL, Liu DT (2014) Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome. Eye (Lond) 28(12):1469\u20131476","journal-title":"Eye (Lond)"},{"issue":"1","key":"4977_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40360-019-0310-1","volume":"20","author":"HY Weng","year":"2019","unstructured":"Weng HY, Huang TL, Chang PY, Wang JK (2019) One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy. BMC Pharmacol Toxicol 20(1):29","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"4977_CR24","doi-asserted-by":"publisher","first-page":"e12840","DOI":"10.1111\/eci.12840","volume":"48","author":"T Qian","year":"2018","unstructured":"Qian T, Li X, Zhao M, Xu X (2018) Polypoidal choroidal vasculopathy treatment options: a meta-analysis. Eur J Clin Investig 48(1):e12840","journal-title":"Eur J Clin Investig"},{"issue":"10","key":"4977_CR25","doi-asserted-by":"publisher","first-page":"e110667","DOI":"10.1371\/journal.pone.0110667","volume":"9","author":"W Wang","year":"2014","unstructured":"Wang W, He M, Zhang X (2014) Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis of comparative studies. PLoS One 9(10):e110667","journal-title":"PLoS One"},{"issue":"1","key":"4977_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3928\/1542-8877-20030101-14","volume":"34","author":"AH Rogers","year":"2003","unstructured":"Rogers AH, Greenberg PB, Martidis A, Puliafito CA (2003) Photodynamic therapy of polypoidal choroidal vasculopathy. Ophthalmic Surg Lasers Imaging 34(1):60\u201363","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"9","key":"4977_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4321\/S0365-66912003000900003","volume":"78","author":"C Torr\u00f3n Fern\u00e1ndez-Blanco","year":"2003","unstructured":"Torr\u00f3n Fern\u00e1ndez-Blanco C, P\u00e9rez Oliv\u00e1n S, Ferrer Novella E, Ruiz-Moreno O, Marcuello Melendo B, Honrubia L\u00f3pez FM (2003) Photodynamic therapy for choroidal neovascularization not caused by age related macular degeneration or pathologic myopia. Arch Soc Esp Oftalmol 78(9):471\u2013476","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"9","key":"4977_CR28","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"HL Tock","year":"2020","unstructured":"Tock HL, Timothy YYL, Kanji T, Tien YW, Lee-Jen C, Paisan R, Colin ST, KiL W, Chui MGC, Nor FN, Ramune P, Philippe M, Adrian K, EVEREST II Study Group (2020) Comparison of ranibizumab with or without Verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II Randomized Clinical Trial. JAMA Ophthalmol 138(9):935\u2013942","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"4977_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","volume":"29","author":"A Laude","year":"2010","unstructured":"Laude A, Cackett PD, Vithana EN, Yeo IY, Wong D, Koh AH, Wong TY, Aung T (2010) Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 29(1):19\u201329","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"4977_CR30","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00018-019-03418-5","volume":"77","author":"A Kauppinen","year":"2020","unstructured":"Kauppinen A (2020) Introduction to the multi-author review on macular degeneration. Cell Mol Life Sci 77(5):779\u2013780","journal-title":"Cell Mol Life Sci"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04977-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-020-04977-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04977-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T14:06:48Z","timestamp":1617286008000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-020-04977-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["4977"],"URL":"https:\/\/doi.org\/10.1007\/s00417-020-04977-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"20 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}